Sanofi India Limited

SANOFI

INE058A01010

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 01:20:25 29/05/2024 pm IST			5-day change	1st Jan Change
8,605 ^INR	+0.05%		-3.52%	+6.66%

16/05	Transcript : Sanofi India Limited, Q1 2024 Earnings Call, May 16, 2024
14/05	Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead	CI

Sanofi India Limited Declares Final Dividend for the Financial Year Ended December 31, 2023

May 14, 2024 at 06:40 pm IST

Sanofi India Limited announced that at the AGM was held on May 14, 2024, the company declaration of Final Dividend of INR 117 per equity share for the Financial Year ended December 31, 2023.

Latest news about Sanofi India Limited

Transcript : Sanofi India Limited, Q1 2024 Earnings Call, May 16, 2024	16/05
Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead	14/05	CI
Sanofi India Limited Declares Final Dividend for the Financial Year Ended December 31, 2023	14/05	CI
Sanofi India's Net Profit Slides in Q1	14/05	MT
Sanofi India Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility	15/04	CI
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee	28/03	CI
Cipla to Distribute Sanofi's CNS Product Line in India	27/03	MT
Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership	26/03	CI
Sanofi India Limited and Emcure Pharmaceuticals Announces Exclusive Distribution Partnership to Broad Broadline Reach of Sanofi's Cardiovascular Brands	13/03	CI
Transcript : Sanofi India Limited, Q4 2023 Earnings Call, Feb 26, 2024	26/02
Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024	23/02	CI
Sanofi India Limited Declares Interim Dividend for the Financial Year Ended 31St December, 2023, Payable on or After 20 March, 2024	23/02	CI
Sanofi India Limited Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Sanofi India Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02	CI
Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024	10/01	CI
Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa	11/12	DJ
Trending : Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials	06/12	DJ
Transcript : Sanofi India Limited, Q3 2023 Earnings Call, Nov 15, 2023	15/11
Sanofi India's CFO Steps Down	09/11	MT
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director	08/11	CI
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Chief Financial Officer, effective November 30, 2023	08/11	CI
Sanofi India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel	17/23/17	CI
Sanofi India Limited Announces Executive Changes	26/23/26	CI

Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.

Sector

Pharmaceuticals

Calendar

23/07/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sanofi India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SANOFI INDIA LIMITED	+6.66%	2.38B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.33%	42.25B
OTSUKA HOLDINGS CO., LTD.	+15.37%	21.27B
SANDOZ GROUP AG	+19.55%	15.23B
CIPLA LIMITED	+20.08%	14.36B
ZYDUS LIFESCIENCES LIMITED	+52.09%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.40%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B

Generic Pharmaceuticals